# A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis

> **NCT07724366** · PHASE3 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.** · enrollment: 400 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** TQH3906 capsules
- **DRUG:** Deucravacitinib tablets 6 mg
- **DRUG:** TQH3906 Capsules placebo
- **DRUG:** Deucravacitinib tablets placebo

## Key facts

- **NCT ID:** NCT07724366
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-02
- **Primary completion:** 2027-09
- **Final completion:** 2028-06
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07724366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07724366, "A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07724366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*